Igc pharma advances igc-ad1 toward clinical trials as a potential anti-amyloid plaque treatment for alzheimer's disease

Potomac, md.--(business wire)-- #ad--igc pharma advances igc-ad1 toward clinical trials as a potential anti-amyloid plaque treatment for alzheimer's disease.

IGC Ratings Summary

IGC Quant Ranking